This technology focuses on developing a patented 5' cap analog (ITRI-Cap), a critical component in mRNA drug production, aiming to bypass existing international patents. It also integrates an advanced one-pot in vitro transcription (IVT) process. Compared to CleanCap®, ITRI-Cap offers simplified synthesis, improved translation efficiency, and reduced production costs. The solution reduces reliance on imported raw materials and high licensing fees, providing CDMO manufacturers with a competitive and flexible alternative, while reinforcing Taiwan’s position in the nucleic acid supply chain.
ITRI is a world-leading applied technology research institute with more than 6,000 outstanding employees. Its mission is to drive industrial development, create economic value, and enhance social well-being through technology R&D. Founded in 1973, it pioneered in IC development and started to nurture new tech ventures and deliver its R&D results to industries. ITRI has set up and incubated companies such as TSMC, UMC, Taiwan Mask Corp., Epistar Corp., Mirle Automation Corp., and Taiwan Biomaterial Co.
Name：Ming-Hsi Wu
Phone：(03)5732575
Address：195, Sec. 4, Chung Hsing Rd., Chutung, Hsinchu, Taiwan 31040, R.O.C.
Using Generative Deep Learning to Predict Drug Response and Survival, a nd Automatically Match Clinical Trials for Advanced Lung Cancer.
Development of HEK293 cell culture process for Coxsackievirus vaccine pr oduction
Innovative Development of Androgen-Metabolizing Probiotics: Functional Gut Microbiome Therapy for Hyperandrogenism Treatment
Development of a Mesenchymal Stem Cell Platform for Multi-Gene Precision Delivery: A Novel Strategy for Cross-Cancer Precision Immunotherapy
Technology maturity：Mass production
Exhibiting purpose：Technology transactions、Product promotion、Display of scientific results
Trading preferences：Negotiate by self
*Organization
*Name
*Phone
*Main Purpose
*Discuss Further
*Job Category
*Overall Rating
*Favorite Area
*Key Tech Focus
*Willing to Receive Updates?
Other Suggestions
Coming soon!